Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by ARS Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026.
- Filed
- May 15, 2026, 6:17 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-225142
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Total revenue | 22,681 | 7,973 |
| Operating expenses: | ||
| Cost of goods sold (including related party amounts of $1,233 and $488, respectively) | 6,286 | 1,094 |
| Research and development (including related party amounts of $667 and $666, respectively) | 4,336 | 2,952 |
| Selling, general and administrative (including related party amounts of $135 and $124, respectively) | 72,204 | 41,104 |
| Total operating expenses | 82,826 | 45,150 |
| Loss from operations | (60,145) | (37,177) |
| Other income (expense), net: |
Item 1. Financial Statements
FAQ
- What is ARS Pharmaceuticals, Inc.'s R&D?
- ARS Pharmaceuticals, Inc. (SPRY) reported R&D of $4.34M in Q1 2026.
- How has ARS Pharmaceuticals, Inc.'s R&D changed year-over-year?
- ARS Pharmaceuticals, Inc.'s R&D increased by 46.9% year-over-year, from $2.95M to $4.34M.
- What is the long-term trend for ARS Pharmaceuticals, Inc.'s R&D?
- Over 3 years (2022 to 2025), ARS Pharmaceuticals, Inc.'s R&D has grown at a -10.5% compound annual growth rate (CAGR), from $18.38M to $13.18M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about ARS Pharmaceuticals, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude